HMGA2 and familial pancreatic carcinoma: In this context, it is noteworthy that our data correlates with a recent extensive in vivo study that implicates HMGA2 expression as a prognostic factor to poor clinical outcomes in human pancreatic cancer patients treated with DNA synthesis inhibitors [51].